Temozolomide (NSC 362856), DNA Alkylator
Por um escritor misterioso
Descrição
Temozolomide (NSC 362856) is an oral active DNA alkylating agent that crosses the blood-brain barrier. Temozolomide is also a proautophagic and proapoptotic agent. Temozolomide is effective against tumor cells that are characterized by low levels of O6-alkylguanine DNA alkyltransferase (OGAT) and a functional mismatch repair system. Temozolomide has antitumor and antiangiogenic effects. - Mechanism of Action & Protocol.
In search of effective therapies to overcome resistance to Temozolomide in brain tumours
Temozolomide in paediatric high-grade glioma: a key for combination therapy?
Selleck Chemical LLC Temozolomide 100mg 85622-93-1 CCRG81045, NSC 362856,TMZ
Phase 1 trial of temozolomide plus irinotecan plus O6‐benzylguanine in adults with recurrent malignant glioma - Quinn - 2009 - Cancer - Wiley Online Library
Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers - ScienceDirect
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules
Temozolomide Supplier, CAS 85622-93-1
Where to Buy 85622-93-1
Novel Imidazotetrazine Evades Known Resistance Mechanisms and Is Effective against Temozolomide-Resistant Brain Cancer in Cell Culture
Temozolomide, CAS:85622-93-1, DNA-methylating antitumor agent; also induces autophagy, High Purity
Frontiers An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?
Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations
de
por adulto (o preço varia de acordo com o tamanho do grupo)
